Elevidys, which is also facing regulatory hurdles in the US, was developed by Sarepta Therapeutics but is sold by Roche outside of the US.

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.

Blood Cancer UK is launching early career grants following a tough pandemic-era funding climate, while US funders worry about federal cuts.

The reorganization and pipeline prioritization is expected to extend the company's operational runway into 2027 and support its long-term growth.

The trial will include patients with non-small cell lung, colorectal, head and neck, and cutaneous cancers with EGFR amplification.

Wall Street analysts warn that if Sarepta Therapeutics doesn't resolve the Elevidys issues, it could jeopardize its ability to repay debt in 2027.

In a new paper, a team from Yale and Fred Hutch has found autoantibody reactivity could predict cancer patients' response to ...

Patients on Itovebi plus Ibrance and fulvestrant had improved progression-free and overall survival compared to Ibrance-fulvestrant alone.

The Global RDH12 Alliance will provide Opus with up to $1.6 million to codevelop a gene therapy for RDH12-associated Leber congenital amaurosis.

Teos announced in May it was winding down operations, following disappointing Phase II study results for its anti-TIGIT antibody.

The FDA had made the request Friday, which Sarepta initially rebuffed, following the death of a third patient treated with one of the firm's gene therapies.

Researchers explored changes in survival outcomes and financial strain for NSCLC patients during a time when new targeted therapies were hitting the market.